Review Papers Claim by Claim

Verdict

The paper reports that HCV infection upregulates miR-373 in primary human hepatocytes and chronic-HCV liver biopsies, and that miR-373 directly targets the 3'UTRs of JAK1 and IRF9, reducing STAT1 phosphorylation, ISRE/ISG56 promoter activity, and ultimately HCV replication is suppressed when miR-373 is knocked down [10.1128/jvi.03085-14]. The evidence chain is unusually complete for a 2015 virology paper: expression profiling in primary hepatocytes, rescue experiments, target-site mutagenesis, and Ago2-RIP binding confirmation.

Notably, miR-373 was not the strongest change in the array — miR-34c-5p rose 9-fold and miR-181c fell 23-fold — yet the authors focused on miR-373 for its predicted JAK/STAT targets. This is a defensible rationale but a potential selection bias the paper does not discuss.

Strengths

• Direct targeting validated twice: dose-dependent luciferase repression of wild-type JAK1/IRF9 3'UTRs, abolished by seed-site mutation, plus Ago2 immunoprecipitation showing enriched JAK1/IRF9/miR-373 in RISC (IFIH1 as a non-targeted negative control) [10.1128/jvi.03085-14].
• Functional rescue: anti-miR-373 restored JAK1, pSTAT1, IRF9, and ISG56 in HCV-infected hepatocytes and reduced HCV RNA/NS3; the reciprocal mimic blocked this effect.
• Pathway context: consistent with known JAK/STAT biology (JAK1→STAT1 phosphorylation→ISGF3 formation) and prior reports that HCV suppresses IFN signaling via other mechanisms.

Critical Limitations

• Sample size: the miRNA array used hepatocytes from only two donors; biopsy cohort is 6 non-HCV vs 8 HCV patients. No multiple-testing correction is described for the array.
• Off-target risk: miR-373 mimics/inhibitors can have unintended targets; no global RNA-seq confirmed that JAK1/IRF9 are the dominant or sole mediators.
• Small effect size: miR-373 upregulation (~1.77–2-fold) is modest; whether this alone explains IFN non-clearance in chronic infection is untested.
• No in vivo validation: no animal model or longitudinal patient data; miR-373 also lacks serum-HCV-load correlation, and the paper notes miR-373 was previously linked to HBV enhancement via NFIB, complicating the mechanism's specificity.
• Therapeutic context outdated: the paper argued for IFN-sparing strategies pre-DAA; since pan-genotypic DAAs achieve >95% SVR, the clinical urgency of targeting miR-373 has diminished, though the mechanism may matter for IFN-nonresponders and chronic coinfections.

What would falsify the conclusion: global transcriptomics showing anti-miR-373's antiviral effect persists in JAK1/IRF9-double-knockout cells, or failure of miR-373 to bind JAK1/IRF9 3'UTRs at endogenous concentrations in primary hepatocytes.

Explore Further